Conflict of Interest in WHO Recommendation Against Ivermectin, by Andrew Bannister

Conflict of interest is nowhere near a strong enough term for a situation in which WHO is basically bought lock, stock, and barrel by interests dead set against Ivermectin. From Andrew Bannister at trialsitenews.com:

Conflict Of Interest in WHO recommendation against Ivermectin

All dangerous diseases are best treated early. A major failure of the global COVID-19 strategy has been to wait a week for the disease to become dangerous, when breathing becomes a problem. Early treatment of COVID, even for those with mild symptoms, prevents later hospitalization. There are several early treatment drugs showing promise but ivermectin leads the pack regarding safety, effectiveness and price. Unfortunately, the biggest players in Western mainstream media are members of the Trusted News Initiative (TNI). The TNI is a story for another day but it’s remarkable that big media companies barely report that they have agreed to promote global vaccination and to make sure any “disinformation myths are stopped in their tracks”[i]. Unfortunately, as a result early treatment seems to be seen as a disinformation myth and is not mentioned. Early treatment is vital in treating serious diseases and COVID-19 is no exception.

Considering the human and economic cost, the avoidance of early treatment with a very safe, effective and off-patent drug is a criminal tragedy of immense proportions and a winning lottery ticket for some pharmaceutical companies that are designing and selling novel patented drugs that could not compete with ivermectin in a free market. Mercks’ molnupiravir, for instance, is seeking an Emergency Use Authorization (EUA) from the FDA and “Merck will receive approximately $1.2 billion to supply approximately 1.7 million courses of molnupiravir to the United States government.”[ii]

Ivermectin doesn’t need an EUA because it passed trials in 1986. It just needs to be recommended to treat COVID-19. However, if ivermectin was officially recognized as an effective treatment, it would legally prevent molnupiravir’s EUA until it passes trials and thus delay or endanger the $1.2 billion deal. An aggravating factor is the fact that molnupiravir (EIDD-2801) could cause harmful genetic mutations. [iii]

Continue reading→

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.